Emergent BioSolutions to Present at the BMO Capital Markets Focus on Healthcare Conference on August 6, 2008
A webcast of this presentation will be available both live and by replay. To access either the live or archived webcast, please proceed to www.emergentbiosolutions.com, and click on the "Investors" link the day of the presentation.
An archived replay of the webcast will be available 24 hours after the live presentation.
About Emergent BioSolutions Inc.
Emergent BioSolutions Inc. is a leading biopharmaceutical company dedicated to one simple mission--to protect life. Emergent develops, manufactures and commercializes vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Emergent's products target infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. The company's marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax infection. www.emergentbiosolutions.com.
SOURCE: Emergent BioSolutions Inc.
Emergent BioSolutions Inc.
Investors Contact:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media Contact:
Tracey Schmitt
Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com